Pharmaceuticals, Biotechnology and Life Sciences
Novo Nordisk has said plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.
Medigene has reported its financial performance in the third quarter of 2023 was in line with the Executive Management Board’s expectations, as the revenues in the third quarter 2023 amounted to EUR 1.6 million compared to EUR 1.4 million in the previous year period (9-month period 2023: EUR 4.6 million), primarily from the partnership with BioNTech.
Lonza has launched two new rapid monocyte activation test (MAT) systems, the PyroCell MAT Rapid System and PyroCell MAT Human Serum (HS) Rapid System, to streamline and simplify rabbit-free pyrogen testing.
Orphelia Pharma, a pharmaceutical company focused on pediatric and orphan medicines, has filed a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for KIZFIZO, the first oral liquid formulation of temozolomide.
Idorsia has announced its financial results for the first nine months of 2023, with net revenues at CHF 29 million, of which CHF 20 million net sales with QUVIVIQ in the US and Europe (Germany, Italy, Switzerland) and CHF 9 million contract revenues.
SOPHiA genetics with with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca have entered a collaboration to work on providing inclusive access to comprehensive cancer testing worldwide.
Xlife Sciences AG has invested CHF 23.3 million in 4D Lifetec AG , acquiring a 20% stake in the company.
Abivax kicked off book-building and the filing of an amended registration statement on Form F-1, to issue approximately 20,325,500 ordinary shares
Basilea Pharmaceutica has entered into an asset purchase agreement with privately owned Gravitas Therapeutics Inc. for GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species.
Vetter Pharma has announced additional investments of €230 million in its new production building, which is currently under construction at the company’s global corporate headquarters site in Ravensburg, as it has recently reached a significant milestone in the construction process, as the shell of the building is now complete, following the start of construction in November 2021.